IBDEI09W ; ; 09-MAY-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 09, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,13265,2)
 ;;=^267546
 ;;^UTILITY(U,$J,358.3,13266,0)
 ;;=206.12^^83^835^13
 ;;^UTILITY(U,$J,358.3,13266,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13266,1,1,0)
 ;;=1^206.12
 ;;^UTILITY(U,$J,358.3,13266,1,8,0)
 ;;=8^Chr Monocytic Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,13266,2)
 ;;=^336477
 ;;^UTILITY(U,$J,358.3,13267,0)
 ;;=206.20^^83^835^55
 ;;^UTILITY(U,$J,358.3,13267,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13267,1,1,0)
 ;;=1^206.20
 ;;^UTILITY(U,$J,358.3,13267,1,8,0)
 ;;=8^Subacute Monocytic Leuk w/o Remiss
 ;;^UTILITY(U,$J,358.3,13267,2)
 ;;=^336863
 ;;^UTILITY(U,$J,358.3,13268,0)
 ;;=206.21^^83^835^54
 ;;^UTILITY(U,$J,358.3,13268,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13268,1,1,0)
 ;;=1^206.21
 ;;^UTILITY(U,$J,358.3,13268,1,8,0)
 ;;=8^Subacute Monocytic Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,13268,2)
 ;;=^267548
 ;;^UTILITY(U,$J,358.3,13269,0)
 ;;=206.22^^83^835^56
 ;;^UTILITY(U,$J,358.3,13269,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13269,1,1,0)
 ;;=1^206.22
 ;;^UTILITY(U,$J,358.3,13269,1,8,0)
 ;;=8^Subacute Monocytic Leuk w/o Remiss
 ;;^UTILITY(U,$J,358.3,13269,2)
 ;;=^336478
 ;;^UTILITY(U,$J,358.3,13270,0)
 ;;=206.80^^83^835^41
 ;;^UTILITY(U,$J,358.3,13270,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13270,1,1,0)
 ;;=1^206.80
 ;;^UTILITY(U,$J,358.3,13270,1,8,0)
 ;;=8^Oth Monocytic Leuk w/ Remission
 ;;^UTILITY(U,$J,358.3,13270,2)
 ;;=^336864
 ;;^UTILITY(U,$J,358.3,13271,0)
 ;;=206.81^^83^835^40
 ;;^UTILITY(U,$J,358.3,13271,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13271,1,1,0)
 ;;=1^206.81
 ;;^UTILITY(U,$J,358.3,13271,1,8,0)
 ;;=8^Oth Monocytic Leuk w/ Remiss
 ;;^UTILITY(U,$J,358.3,13271,2)
 ;;=^267551
 ;;^UTILITY(U,$J,358.3,13272,0)
 ;;=206.82^^83^835^39
 ;;^UTILITY(U,$J,358.3,13272,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13272,1,1,0)
 ;;=1^206.82
 ;;^UTILITY(U,$J,358.3,13272,1,8,0)
 ;;=8^Oth Monocytic Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,13272,2)
 ;;=^336479
 ;;^UTILITY(U,$J,358.3,13273,0)
 ;;=206.90^^83^835^62
 ;;^UTILITY(U,$J,358.3,13273,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13273,1,1,0)
 ;;=1^206.90
 ;;^UTILITY(U,$J,358.3,13273,1,8,0)
 ;;=8^Unspec Monocytic Leuk w/o Remiss
 ;;^UTILITY(U,$J,358.3,13273,2)
 ;;=^336865
 ;;^UTILITY(U,$J,358.3,13274,0)
 ;;=206.91^^83^835^61
 ;;^UTILITY(U,$J,358.3,13274,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13274,1,1,0)
 ;;=1^206.91
 ;;^UTILITY(U,$J,358.3,13274,1,8,0)
 ;;=8^Unspec Monocytic Leuk in Remiss
 ;;^UTILITY(U,$J,358.3,13274,2)
 ;;=^267554
 ;;^UTILITY(U,$J,358.3,13275,0)
 ;;=206.92^^83^835^60
 ;;^UTILITY(U,$J,358.3,13275,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13275,1,1,0)
 ;;=1^206.92
 ;;^UTILITY(U,$J,358.3,13275,1,8,0)
 ;;=8^Unspec Monocytic Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,13275,2)
 ;;=^336480
 ;;^UTILITY(U,$J,358.3,13276,0)
 ;;=207.00^^83^835^3
 ;;^UTILITY(U,$J,358.3,13276,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13276,1,1,0)
 ;;=1^207.00
 ;;^UTILITY(U,$J,358.3,13276,1,8,0)
 ;;=8^AC Eryth & Erythroleuk w/o Remiss
 ;;^UTILITY(U,$J,358.3,13276,2)
 ;;=^336866
 ;;^UTILITY(U,$J,358.3,13277,0)
 ;;=207.01^^83^835^1
 ;;^UTILITY(U,$J,358.3,13277,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13277,1,1,0)
 ;;=1^207.01
 ;;^UTILITY(U,$J,358.3,13277,1,8,0)
 ;;=8^AC Eryth & Erythroleuk in Relapse
 ;;^UTILITY(U,$J,358.3,13277,2)
 ;;=^267556
 ;;^UTILITY(U,$J,358.3,13278,0)
 ;;=207.02^^83^835^2
 ;;^UTILITY(U,$J,358.3,13278,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13278,1,1,0)
 ;;=1^207.02
 ;;^UTILITY(U,$J,358.3,13278,1,8,0)
 ;;=8^AC Eryth & Erythroleuk in Relapse
 ;;^UTILITY(U,$J,358.3,13278,2)
 ;;=^336481
 ;;^UTILITY(U,$J,358.3,13279,0)
 ;;=207.10^^83^835^9
 ;;^UTILITY(U,$J,358.3,13279,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13279,1,1,0)
 ;;=1^207.10
 ;;^UTILITY(U,$J,358.3,13279,1,8,0)
 ;;=8^Chr Erythremia w/o Remission
 ;;^UTILITY(U,$J,358.3,13279,2)
 ;;=^336867
 ;;^UTILITY(U,$J,358.3,13280,0)
 ;;=207.11^^83^835^8
 ;;^UTILITY(U,$J,358.3,13280,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13280,1,1,0)
 ;;=1^207.11
 ;;^UTILITY(U,$J,358.3,13280,1,8,0)
 ;;=8^Chr Erythremia in Remission
 ;;^UTILITY(U,$J,358.3,13280,2)
 ;;=^267558
 ;;^UTILITY(U,$J,358.3,13281,0)
 ;;=207.12^^83^835^7
 ;;^UTILITY(U,$J,358.3,13281,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13281,1,1,0)
 ;;=1^207.12
 ;;^UTILITY(U,$J,358.3,13281,1,8,0)
 ;;=8^Chr Erythremia in Relapse
 ;;^UTILITY(U,$J,358.3,13281,2)
 ;;=^336482
 ;;^UTILITY(U,$J,358.3,13282,0)
 ;;=207.20^^83^835^28
 ;;^UTILITY(U,$J,358.3,13282,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13282,1,1,0)
 ;;=1^207.20
 ;;^UTILITY(U,$J,358.3,13282,1,8,0)
 ;;=8^Megakaryocytic Leuk w/o Remission
 ;;^UTILITY(U,$J,358.3,13282,2)
 ;;=^336868
 ;;^UTILITY(U,$J,358.3,13283,0)
 ;;=207.21^^83^835^27
 ;;^UTILITY(U,$J,358.3,13283,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13283,1,1,0)
 ;;=1^207.21
 ;;^UTILITY(U,$J,358.3,13283,1,8,0)
 ;;=8^Megakaryocytic Leuk in Remission
 ;;^UTILITY(U,$J,358.3,13283,2)
 ;;=^267560
 ;;^UTILITY(U,$J,358.3,13284,0)
 ;;=207.22^^83^835^26
 ;;^UTILITY(U,$J,358.3,13284,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13284,1,1,0)
 ;;=1^207.22
 ;;^UTILITY(U,$J,358.3,13284,1,8,0)
 ;;=8^Megakaryocytic Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,13284,2)
 ;;=^336483
 ;;^UTILITY(U,$J,358.3,13285,0)
 ;;=207.80^^83^835^47
 ;;^UTILITY(U,$J,358.3,13285,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13285,1,1,0)
 ;;=1^207.80
 ;;^UTILITY(U,$J,358.3,13285,1,8,0)
 ;;=8^Oth Spec Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,13285,2)
 ;;=^336869
 ;;^UTILITY(U,$J,358.3,13286,0)
 ;;=207.81^^83^835^46
 ;;^UTILITY(U,$J,358.3,13286,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13286,1,1,0)
 ;;=1^207.81
 ;;^UTILITY(U,$J,358.3,13286,1,8,0)
 ;;=8^Oth Spec Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,13286,2)
 ;;=^267562
 ;;^UTILITY(U,$J,358.3,13287,0)
 ;;=207.82^^83^835^45
 ;;^UTILITY(U,$J,358.3,13287,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13287,1,1,0)
 ;;=1^207.82
 ;;^UTILITY(U,$J,358.3,13287,1,8,0)
 ;;=8^Oth Spec Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,13287,2)
 ;;=^336484
 ;;^UTILITY(U,$J,358.3,13288,0)
 ;;=208.00^^83^835^21
 ;;^UTILITY(U,$J,358.3,13288,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13288,1,1,0)
 ;;=1^208.00
 ;;^UTILITY(U,$J,358.3,13288,1,8,0)
 ;;=8^Leukemia Unspec w/o Remission
 ;;^UTILITY(U,$J,358.3,13288,2)
 ;;=^336870
 ;;^UTILITY(U,$J,358.3,13289,0)
 ;;=208.01^^83^835^20
 ;;^UTILITY(U,$J,358.3,13289,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13289,1,1,0)
 ;;=1^208.01
 ;;^UTILITY(U,$J,358.3,13289,1,8,0)
 ;;=8^Leukemia Unspec in Remission
 ;;^UTILITY(U,$J,358.3,13289,2)
 ;;=^267566
 ;;^UTILITY(U,$J,358.3,13290,0)
 ;;=208.02^^83^835^19
 ;;^UTILITY(U,$J,358.3,13290,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13290,1,1,0)
 ;;=1^208.02
 ;;^UTILITY(U,$J,358.3,13290,1,8,0)
 ;;=8^Leukemia Unspec in Relapse
 ;;^UTILITY(U,$J,358.3,13290,2)
 ;;=^336485
 ;;^UTILITY(U,$J,358.3,13291,0)
 ;;=208.10^^83^835^12
 ;;^UTILITY(U,$J,358.3,13291,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13291,1,1,0)
 ;;=1^208.10
 ;;^UTILITY(U,$J,358.3,13291,1,8,0)
 ;;=8^Chr Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,13291,2)
 ;;=^336871
 ;;^UTILITY(U,$J,358.3,13292,0)
 ;;=208.11^^83^835^11
 ;;^UTILITY(U,$J,358.3,13292,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13292,1,1,0)
 ;;=1^208.11
 ;;^UTILITY(U,$J,358.3,13292,1,8,0)
 ;;=8^Chr Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,13292,2)
 ;;=^267569
 ;;^UTILITY(U,$J,358.3,13293,0)
 ;;=208.12^^83^835^10
 ;;^UTILITY(U,$J,358.3,13293,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13293,1,1,0)
 ;;=1^208.12
 ;;^UTILITY(U,$J,358.3,13293,1,8,0)
 ;;=8^Chr Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,13293,2)
 ;;=^336486
 ;;^UTILITY(U,$J,358.3,13294,0)
 ;;=208.20^^83^835^53
 ;;^UTILITY(U,$J,358.3,13294,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13294,1,1,0)
 ;;=1^208.20
 ;;^UTILITY(U,$J,358.3,13294,1,8,0)
 ;;=8^Subacute Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,13294,2)
 ;;=^336872
 ;;^UTILITY(U,$J,358.3,13295,0)
 ;;=208.21^^83^835^52
 ;;^UTILITY(U,$J,358.3,13295,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13295,1,1,0)
 ;;=1^208.21
 ;;^UTILITY(U,$J,358.3,13295,1,8,0)
 ;;=8^Subacute Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,13295,2)
 ;;=^267572
 ;;^UTILITY(U,$J,358.3,13296,0)
 ;;=208.22^^83^835^51
 ;;^UTILITY(U,$J,358.3,13296,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13296,1,1,0)
 ;;=1^208.22
 ;;^UTILITY(U,$J,358.3,13296,1,8,0)
 ;;=8^Subacute Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,13296,2)
 ;;=^336487
 ;;^UTILITY(U,$J,358.3,13297,0)
 ;;=208.80^^83^835^38
 ;;^UTILITY(U,$J,358.3,13297,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13297,1,1,0)
 ;;=1^208.80
 ;;^UTILITY(U,$J,358.3,13297,1,8,0)
 ;;=8^Oth Leuk Unspec Cell Type w/o Rem
 ;;^UTILITY(U,$J,358.3,13297,2)
 ;;=^336873
 ;;^UTILITY(U,$J,358.3,13298,0)
 ;;=208.81^^83^835^37
 ;;^UTILITY(U,$J,358.3,13298,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13298,1,1,0)
 ;;=1^208.81
 ;;^UTILITY(U,$J,358.3,13298,1,8,0)
 ;;=8^Oth Leuk Unspec Cell Type w/ Rem
 ;;^UTILITY(U,$J,358.3,13298,2)
 ;;=^267574
 ;;^UTILITY(U,$J,358.3,13299,0)
 ;;=208.82^^83^835^36
 ;;^UTILITY(U,$J,358.3,13299,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13299,1,1,0)
 ;;=1^208.82
 ;;^UTILITY(U,$J,358.3,13299,1,8,0)
 ;;=8^Oth Leuk Unspec Cell Type in Relap
 ;;^UTILITY(U,$J,358.3,13299,2)
 ;;=^336488
 ;;^UTILITY(U,$J,358.3,13300,0)
 ;;=209.00^^83^835^25
 ;;^UTILITY(U,$J,358.3,13300,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13300,1,1,0)
 ;;=1^209.00
 ;;^UTILITY(U,$J,358.3,13300,1,8,0)
 ;;=8^Mal Carcinoid Tumor,Sm Intestine
 ;;^UTILITY(U,$J,358.3,13300,2)
 ;;=^336721
 ;;^UTILITY(U,$J,358.3,13301,0)
 ;;=209.01^^83^835^22
 ;;^UTILITY(U,$J,358.3,13301,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13301,1,1,0)
 ;;=1^209.01
 ;;^UTILITY(U,$J,358.3,13301,1,8,0)
 ;;=8^Mal Carcinoid Tumor,Duodenum
 ;;^UTILITY(U,$J,358.3,13301,2)
 ;;=^336490
